NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Phase 1

Completed

Conditions: Stage IV Melanoma
Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Melanoma
Stage III Melanoma

Interventions: Drug: imatinib mesylate
Biological: bevacizumab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-12-11

Last Posted Date: 2018-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00074308

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: omacetaxine mepesuccinate
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-12-05

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00003694

Locations: 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States

Fenretinide in Treating Children With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Neuroblastoma

Interventions: Drug: fenretinide

First Posted Date: 2003-11-26

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00003191

Locations: 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

and more 23 locations

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Phase 1

Completed

Conditions: Recurrent Bladder Cancer
Stage II Bladder Cancer
Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Stage I Bladder Cancer

Interventions: Biological: Ad5CMV-p53 gene

First Posted Date: 2003-11-25

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00003167

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Insulin-Dependent

First Posted Date: 2003-11-20

Last Posted Date: 2010-01-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 12

Registration Number: NCT00073255

Locations: 🇺🇸
Columbia University, New York, New York, United States

Islet Transplantation for Patients With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

First Posted Date: 2003-11-20

Last Posted Date: 2010-01-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 10

Registration Number: NCT00073281

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

Insulin Resistance and Insulin Secretion

Not Applicable

Withdrawn

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2003-11-20

Last Posted Date: 2018-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00073294

Locations: 🇺🇸
Columbia Presbyterian Medical Center/ Irving Center, New York, New York, United States
🇺🇸
Russ Berrie Pavilion, New York, New York, United States

Low-Dose Leptin and the Formerly-Obese

Phase 3

Conditions: Obesity

Interventions: Drug: Leptin
Behavioral: Dietary modification
Drug: T3 repletion

First Posted Date: 2003-11-19

Last Posted Date: 2015-06-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT00073242

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

Prevention of Type 2 Diabetes Mellitus in Children

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2003-11-19

Last Posted Date: 2010-01-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 300

Registration Number: NCT00073268

Locations: 🇺🇸
Russ Berrie Pavilion, New York, New York, United States
🇺🇸
New York Presbyterian Hospital, New York, New York, United States

Diabetes Therapy to Improve BMI and Lung Function in CF

Phase 3

Completed

Conditions: Cystic Fibrosis
Diabetes Mellitus

Interventions: Drug: Insulin Asparte
Drug: Repaglinide

First Posted Date: 2003-11-14

Last Posted Date: 2012-02-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 108

Registration Number: NCT00072904

Locations: 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy